Synthesis and characterization of antibacterial drug loaded β-tricalcium phosphate powders for bone engineering applications


Topsakal A., Ekren N., Kilic O., Oktar F. N., Mahirogullari M., Ozkan O., ...Daha Fazla

Journal of Materials Science: Materials in Medicine, cilt.31, sa.2, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 31 Sayı: 2
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1007/s10856-019-6356-1
  • Dergi Adı: Journal of Materials Science: Materials in Medicine
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, PASCAL, Aerospace Database, Agricultural & Environmental Science Database, Applied Science & Technology Source, Biotechnology Research Abstracts, Chemical Abstracts Core, Chimica, Communication Abstracts, Compendex, Computer & Applied Sciences, EMBASE, INSPEC, MEDLINE, Metadex, Civil Engineering Abstracts
  • Marmara Üniversitesi Adresli: Evet

Özet

© 2020, Springer Science+Business Media, LLC, part of Springer Nature.Powders of β-tricalcium phosphate [β-TCP, β-Ca3(PO4)2] and composite powders of β-TCP and polyvinyl alcohol (PVA) were synthesized by using wet precipitation methods. First, the conditions for the preparation of single phase β-TCP have been delineated. In the co-precipitation procedure, calcium nitrate and diammonium hydrogen phosphate were used as calcium and phosphorous precursors, respectively. The pH of the system was varied in the range 7–11 by adding designed amounts of ammonia solution. The filtered cakes were desiccated at 80 °C and subsequently calcined at different temperatures in the range between 700–1100 °C. Later on, rifampicin form II was used to produce drug-loaded β-TCP and PVA/β-TCP powders. All the synthesized materials have been characterized from morphological (by scanning electron microscopy) and structural-chemical (by X-ray diffraction and Fourier transform infrared spectroscopy) point of view. The drug loading capacity of the selected pure β-TCP powder has been assessed. The biological performance (cytocompatibility in fibroblast cell culture and antibacterial efficacy against Escherichia coli and Staphylococcus aureus) has been tested with promising results. Application perspectives of the designed drug-bioceramic-polymer blends are advanced and discussed. [Figure not available: see fulltext.].